Showing posts with label Infectious Disease. Show all posts
Showing posts with label Infectious Disease. Show all posts

May 19, 2013

I Think it's a Good Time to be a $PVCT Shareholder

Shareholders are closer to the end-game for the stock than to their journey's beginning. The company's  life sciences technology is head and shoulders above its peers. The lead compound presents a compelling clinical value proposition capable, perhaps, of indeed shifting the paradigm of cancer treatment (and treatment of inflammatory skin disorders). The drug already is productized, with a product business proposition to match that of the underlying technology. Provectus appears to be nearing transparency regarding regulatory clarity for oncology. The company also appears to be nearing certain license deals that will provide initial market validation. In sum, management, Provectus and its shareholders are nearing the end-game.

Provectus' technology is a game changer, productized to effect the change, and can be delivered and scaled to profit from the change to come.

The technology, PV-10 for oncology, is an effective local treatment capable of as effectively treating distant disease and visceral metastases. The drug, through expression of antigens in context in tumors into which PV-10 is injected fortifies the immune system against cancerous agents. Immunization occurs because PV-10's chemoablation causes rapid, complete, durable necrosis of tumor lesions.

"Scientists have been trying for decades to understand why the body's immune system didn't see cancer cells as the enemy and attack them. Recent discoveries revealed that tumors are adept at cloaking themselves by hijacking the body's own mechanism for preventing the system's T-cells, the infection- and disease-fighting cells of the immune system, from running amok against healthy tissue."

The above quote from Wall Street Journal (WSJ) article New Cancer Drugs Harness Power of Immune System (5/15/13) is not quite on-point. Rather, the quote below from Bloomberg article Human Immune-Boosting Cancer Drugs Seen Extending Lives (5/12/13) is more to the point.

"Now many believe that by strengthening the immune system’s ability to identify and kill cancer cells, they can broaden the attack so it will fight any dangerous malignancy. “You’re setting up a fair fight” with the disease, said Nils Lonberg, a senior vice president at Bristol-Myers, in a telephone interview. “The immune system is just as adaptable as the cancer.”"

How do you strengthen the immune system? Medical science has done it before with infectious diseases. Immune systems can be overwhelmed and, thus, are unable to help the human body fight back. Antibiotics themselves do not cure patients of infectious diseases that have afflicted them. Rather, the immune system cures the hosts with the help of antibiotics. Treating infectious diseases requires that antibiotics should have near absolute specificity for the infectious agent. Tough infections require multiple agents.

I think it's a good time to be a Provectus shareholder.

The volume of the conversations about immunotherapy has grown much, much louder. Take Xconomy's Luke Timmerman's article Genentech Follows Fast at ASCO as Cancer Immunotherapy Picks Up (5/15/13) for example.

"Genentech made its name in cancer by creating targeted antibody drugs that zero in on tumor cells while mostly sparing healthy tissue. Now it’s seeking to compete in the next wave of cancer immunotherapies, which are designed to spark the immune system to attack tumors like a virus."

Or take NBC's Nightly News report Immunotherapy targets cancer cells with remarkable results (5/15/13).

"Cancer cells typically put up a chemical shield to protect against the body’s disease-fighting T cells. But immunotherapy can break down the shield and let the T cells get to work."

The more the biopharmaceuticals industry, investing community and general public talk about immunotherapy, the better the environment or atmosphere for PV-10 and Provectus to flourish.

From the same WSJ article above: "More broadly, Leerink [Swann, a middle market investment bank] believes the "immuno-oncology" drug market could amount to a $20 billion category annually, putting it on a par with the cholesterol-lowering statin market at its height."

From dendritic cells (Dendreon's Provenge) to antitumor antibodies (Bristol-Myers' anti-CTLA-4 agent Yervoy) to immune checkpoint blockades (ASCO 2013's anti-PD1 and anti-PDL-1 agents):

"The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and immunology...[t]he pillars of human cancer therapy have historically been surgery, radiotherapy, and chemotherapy, but a fourth modality of immunotherapy has been well documented since 1890..." (Kirkwood et al.).

Big Pharma is tacking closer to the ultimate goal, but they mostly still are sailing wide of the objective.

"If the new generation of immune therapies lives up to its promise, “this is going to be a paradigm shift for treating cancer,” said Merck senior vice president Gary Gilliland in an interview. “We are pretty good at shrinking tumors, but not good at getting rid of them. Immune therapy is a way to begin to approach that.”"

Yes, Big Pharma is pretty good at shrinking cancerous tumors, but not yet good enough at making them go away.

Craig's postulation that you treat cancer like you treat an infectious disease requires a/the drug treatment to possess near absolute specificity for diseased tissue (spare normal tissue and clear rapidly from it) and induce a host response (combined apoptosis-autophagy of treated targets because intralesional delivery produces a “vaccine-like” systemic effect that enhances normal human body defenses) over a very wide range of activity (broad spectrum antibiotic-like)


PV-10 chemoablation causes rapid, complete, durable necrosis of tumor lesions.

I think it's a good time to be a Provectus shareholder.

The general discourse at the moment about immunotherapies, however, is far from well understood or a consensus. Take last week's exchange on Adam Feuerstein's Twitter feed @adamfeuerstein below.


Feuerstein had been explaining the fundamental bear case for Vical's Allovectin-7, but aside from perhaps some valid trial design questions, his "red flags" included a lack of positive statements by melanoma experts and institutional healthcare investors as well as a lack of immune-related toxicity by Allovectin-7. Church is not a fan of immune-related toxicity because of the long-term dangers of altering the immune system in order to use it. All of this despite the on-point replies of other respondents: directing T-cells to attack tumors rather than a broad uncontrolled response, the beauty of local treatment is limited toxicity, revolutionary if the local treatment works on visceral mets, etc.

Many monoclonal immunotherapies do cause terrible toxicities, which are related not just related to "taking the brakes off" the immune system. Their target antigens are not only on/in the immune cells they wish to suppress. Just like chemotherapy agents, immunotherapy agents also can cause collateral damage with more adverse side effects like cancer and death.

The nature of the conversation Feuerstein, Church and the others need to have has to be deeper and more substantive. It's too simplistic to say Allovectin-7 does or will not work. Whether it's Allovectin-7 or talimogene laherparepvecone (T-Vec, formerly OncoVEX), or PV-10 itself, one has to balance positive effects with side effects. Think of it as a biological signal-to-noise ratio. One can titer up dosages until one sees bad things happen.

I think Pfizer probably refused to do this with its anti-CTLA-4 agent tremelimumab, which is why it has a greater failure record in clinical trials than it's Bristol-Myers' ipilimumab. Bristol-Myers probably had a higher tolerance for "bad things to happen" in order to suss out the optimal or near-optimal signal-to-noise or benefit-to-side-effect ratio.

Remind yourself of Provectus' combination therapy work at AACR 2013 utilizing PV-10 and a systemic anti-CTLA-4 antibody. The highest dose of the latter killed the murine subjects more quickly. Lower doses were less effective but also less dangerous. Interestingly, the results the company concluded that while PV-10 is highly effective when all existing tumor is accessible for injection, for visceral or other inaccessible disease the combination of PV-10 with CTLA-4 blockade has important potential synergy. Nevertheless, the apparent toxicity at high doses of the anti-CTLA-4 antibody markedly reduced the effect of the antibody alone and the combination of PV-10 and the antibody.

If an immunotherapy is working, there has to be some response (e.g., inflamation, redness, blistering, itching, etc.). These "side effects" come with the territory, and merely are signs the immune system is now in the game. So, while one indeed is generating a toxic response by recruiting the immune system, the key is focusing this toxicity as much as possible.

The problem with Yervoy, and perhaps immunotherapies like anti-PD-1, anti-PDL-1 agents and other treatments, is the collateral damage they cause to the body. PV-10's great strength has been and is its ability to the target only what it kills and kill only what it targets. Another strength is the drug's ability to generate a very specific, targeted, immune response with very little collateral damage to anything but the tumor itself. So, some blistering occurs, body temperature rises, etc. Nothing more.

I think it's a good time to be a Provectus shareholder.

Still, regulatory clarity has to become transparent. Is it an MM Phase 3 trial under SPA powered for for a 6-month progressional free survival for PV-10 vs. 2-month plus PFS for the comparator DTIC?Or is it breakthrough designation therapy and accelerated approval or another accelerated pathway?

Further still, commercial validation through one or more meaningful license transactions (global, regional, dermatology) is required. For example, will it be Hisun-Pfizer Pharmaceuticals in China? Or another company or entity? The Hisun-Pfizer joint venture was established in 2012 to sell off-patent medicines in China and other emerging markets. But economics are economics. Pfizer's 49% equity ownership and thus 49% ownership of any PV-10 sales in China would be a strong inducement to widening the entity's mandate through a license deal with Provectus.

Who will it be in India? In Japan? When will PH-10 be licensed, and to whom?

Provectus is squarely in the eye of key cancer patient advocates. The company participated in Melanoma Research Alliances' (MRA's) Fifth Annual Scientific Retreat in February. In April Peter joined MRA's President and CEO Wendy Selig, LiveSTRONG's President and CEO and Provectus corporate advisory board member Doug Ulman, Moffitt Cancer Research Center's Dr. Shari Pilon-Thomas and some media for dinner.

Key opinion leaders like Moffitt's Dr. Jeff Weber and Dr. Vernon Sondak and Pfizer's Dr. Craig Eagle are enthused about PV-10 as both a monotherapy and combination therapy.

More data is on the way. And data is driving and will drive the deals.

Yes, I think it's a good time to be a Provectus shareholder.

April 2, 2013

$PVCT: Treating Cancer Like An Infectious Disease by Craig Dees

(c. 2007)

Introduction

Most “high-tech” medicines are not the life-savers they are believed to be. The advent of modern sanitation, especially toilets and clean water, has saved more lives than all medicines combined. As a designer of new drugs this statement dismays me, but its accuracy cannot be questioned.

Among modern medicines, vaccines and antibiotics have undoubtedly saved the most lives. These agents have been so successful because they boost or assist natural defense mechanisms rather than attempting to supplant them.

Virtually any disease defense system designed by Nature, with more than 150 million years of practice, must be intrinsically more effective than so-called “rationally designed” drug, whose discovery is based on the current state of understanding of biology. The selection system for achieving the very best defense system is harsh; a high price is paid for coming in second. Nature’s grading scale rewards a few A+ students with survival, and punishes those receiving lower marks with death or extinction.

Mother Nature’s grading scale rewards the most adaptable mechanisms with survival, and punishes the rest with death or extinction.

Arguments that we can substantially improve on nature, regardless of whether it’s the handiwork of God or of evolution, defies common sense. Even the remarkable products of animal husbandry, plant genetics, and transgenics derive from manipulation of  genetic materials already present in nature.

Paradoxically, even the recognized miracle drugs, antibiotics and vaccines, do not cure bacterial or viral diseases. Antibiotics merely hold the microbial invaders at bay until the host’s own defenses can clear the infection. This mechanism holds for most, but not all infectious diseases. Drug cocktails have transformed AIDS, for example, from a universally fatal infection into a chronic, manageable disease. But AIDS is incurable – not due to any shortcoming of AIDs drugs, but because the human body never evolved a home-grown mechanism for curing the disease.

Similarly, vaccines enhance natural immunity by stimulating the host’s normal defenses in anticipation of meeting a microbial or viral invader. Vaccines have little effect, if any, once the host is infected. One can gauge the potential success of a proposed vaccine treatment simply by testing whether the host can mount an immune response, even a weak one, on its own.

A great deal of time and effort have gone into creating an AIDS vaccine.  One need not be a world-class immunologist or virologist to predict the probable success in creating such a vaccine. Instead, one only needs ask one or two questions. The first question to ask is, “Can HIV-positive individuals survive infection (presumably as a result of developing natural immunity)?”  The answer is “No!” since humans have not yet evolved immune mechanisms capable of significantly altering the course of HIV infection.  So what are the chances of developing an AIDS vaccine? Not zero, but most likely quite poor. The human immune system, developed over 150 million-plus years of evolution, is far more effective than our feeble attempts at creating drug-induced immunity. It is more likely that HIV will evolve into a less deadly form than that our immune systems will develop a means for countering this catastrophic infection.

Our approaches to treating cancer directly defy the rationales underlying the effectiveness of vaccines and antibiotics. This may explain the relative lack of success in effecting long-term remissions and cures through conventional cancer therapies, principally chemotherapy and radiation. And it clearly explains, at least in part, the severe side effects resulting from conventional cancer treatments.

Chemotherapy remains primarily a regimen of administering highly toxic agents targeted toward cancer cells’ reproductive mechanisms. An unfortunate side effect almost always is damage to the cells’ genetic material. Chemotherapy agents are among the most potent mutagens, and carcinogens known, so even if these agents clear the disease, a long-term consequence may be a new cancer induced by the treatment itself.
It’s a long, boring flight between London and Charlotte, NC. Normally I try to read, write,  or watch whatever movies are available on the plane. On a recent flight I ran out of material to keep me entertained and picked up my neighbor’s Time Magazine. Thumbing through, I noticed the obituary section and a prominently displayed entry on the passing of a world-class viral pathologist who had trained me. Among the greatest lessons I learned from him were to value scientific integrity and to place scientific data above political or economic pressure. The obituary described my mentor’s death from cancer. With tears streaming down my face, I returned the magazine to the man in the next seat.  By the time I landed, many calls were awaiting me from virologists and immunologists locate all over the world. When I answered one, he said, “We knew you would want to be at the funeral but we couldn’t find you.”  “London.” was all I said, before asking, “What happened?” The answer was that a new cancer had developed as a result of cancer therapy he had received 30 years prior to defeat colon cancer. The new cancer was so virulent that nothing could stop it. It was so bizarre that the pathologists were puzzled as to what exactly it was and what its origins were. So he really hadn’t completely defeated his initial cancer, but was quite lucky that he had 30 years before the new cancer developed due to the treatments he received.
I would argue that the effects of toxic, carcinogenic cancer treatments might do more damage to anti-cancer defenses than to the cancer itself. Any high-affinity immune cell clone, when it recognizes its target, becomes highly activated, which makes it highly susceptible to death by radiation or chemotherapy. In many cases, immune system mechanisms are affected more than the tumor itself, and often the cancer-fighting clones become fully depleted and never return. Therefore, the first casualty of toxic cancer drugs may very well be the defenses that have been evolving for millions of years to fight cancer.

Furthermore, relatively ineffective chemotherapies and radiation are more likely to train the immune system to tolerate the cancer (similar to low-dose tolerance therapy used to treat allergies), as opposed to stimulating a full-scale attack on it. We commonly treat cancer with systemic doses of chemotherapy or fractionated doses of radiation. While almost immediate ablation of the anti-tumor defenses is likely to occur, tumors generally shrink slowly over time. The immune system responds in direct proportion to the strength of a threat. Thus, to maximize their effectiveness, killed-virus vaccines usually contain an adjuvant designed to stimulate a robust immune response, usually through limited tissue damage. Absent this tissue insult, the immune system may simply ignore a vaccine antigen. Similarly, the immune system may not be prompted to attack slowly-shrinking tumors, and in the worst case may be coaxed into leaving the tumor alone.

To become safer and more effective, cancer therapies need to engage the natural anti-cancer defenses instead of destroying them. As radical as it may sound, we need treat cancer like an infectious disease.

As radical as it may sound, we need treat cancer like an infectious disease.
While the etiology of many cancers remains unknown, more and more appear to have a link to infectious agents. We know that certain viruses can transform cells to a cancerous state. Hepatitis B virus is associated with liver cancer; human T-cell leukemia virus is known to cause human leukemia, papilloma viruses are associated with nasopharyngeal and cervical carcinomas. There is evidence that both prostate and breast cancers may be caused by viruses as well. One wonders how many other serious cancers possess a link to viruses (or even bacteria). The recently approved vaccine against human papilloma virus, believed to be the causative agent in cervical cancer, may serve as a model for the state of tomorrow’s cancer prevention strategies.  
It will be interesting to observe whether the incidence of prostate cancer in men declines as the use of the papilloma virus vaccine becomes prevalent. While no virus has yet been associated with prostate cancer, researchers have not identified any relevant genetic aberration that explains this disease affecting almost 220,000 men annually in the U.S. 
How to Engage the Immune System

One way to stimulate natural anti-cancer defenses is to kill the tumor rapidly, thereby stimulating the immune system via the destruction of tissue. A simple way to do this is to treat the tumor by intralesional injection of a suitable anti-tumor agent. However, such drugs must possess high specificity for tumors. Previous attempts to ablate tumors directly using standard chemotherapy agents have been unsuccessful because these drugs show little or no preference for tumors over normal tissues. Intralesional injection with such agents produces the same toxic damage to natural anti-cancer immunity as occurs with systemic treatment.

A second way to engage the immune system is to present antigens to the cells responsible for selecting the best antigens, which then present these antigens to high-affinity clones of both effector cells and cells that function as “Concert Masters” by maintaining immunologic memory (a mixed populace of cells so named based on their common function as orchestrators of the immune system). Photodynamic anti-cancer agents are superior in delivering antigens to antigen presenting cells (APCs), allowing these cells to process the antigens, select appropriate targets, present selected antigens to immune system cells with high affinity for the targets, and stimulate cancer-killing cells to replicate .In other words, they are allowed to do the job for which nature prepared them.

Finally, tumor antigens must be viewed in context. Physical ablative techniques, such as heating or freezing tissue, are likely to destroy fragile antigens and disrupt their relevant contextual structures. Disruption of cell membranes and removal of lipids, proteins, and complex carbohydrates destroys the antigens’ context, which is what immune system cells respond to.  Thermal destruction may also denature potential antigens, changing their chemical structure so that they are no longer representative of the tumor cell. In order to work, rapid destruction of tumors must preserve antigenic structure and biological context.

Clinical-stage cancer vaccines based on antigen presentation are likely to fail for many of the reasons given above. The antigen chosen by drug developers is very likely not the best one, or the only one, that the immune system would choose on its own. Further, only one antigen has been selected whereas natural presentation of a potpourri of cellular antigens allows the selection of multiple targets, perhaps on an individual basis, and their subsequent presentation to high affinity T and B cells. Finally, generating the response in vitro, compared with normal antigen-presenting mechanisms, hinders the ability to generate an effective immune response.
The cancer antigen approach suffers from a complete loss of contextual presentation of the tumor targets. When I was first taught immunology, the prevailing dogma held that there was never an anti-self response. However, this is now known to be incorrect. In addition to targeting “foreign” threats such as bacterial infections, the immune system targets things it recognizes as “altered-self.”  The immune system can be thought of has having a very highly specific and nearly perfect “picture” of what “self” looks like. Anything different is subject to attack. Therefore, generating the optimal anti-tumor response through a target antigen requires cells to experience the antigen in vivo, in its natural conformation and context.  
While we have learned many things about how the immune system works, much still remains a “black box.” We know what goes into the box, and can quantify outputs, but we are clueless of the intervening mechanisms, particularly how to harness the natural immune response for treating cancer.
Another technique currently under development for enhancing anti-tumor response entails harvesting high-affinity immune cells which are stimulated and amplified in vitro. For example, white cells exhibiting tumor antigen are harvested, stimulated by chemokines, then re-introduced into the patient. Killed tumor antigens may also be delivered to the patient in the form of a “vaccine” which in theory should help generate a maximum immune response.

This approach, while more ingenious and practical than the cell-based treatment, still suffers in that the response generated in vitro may not fully mimic that produced in vivo.

The last liability of current anti-tumor immunotherapies is their novelty, which often relegates them to last-ditch rescue therapy after surgery, radiation and chemotherapy cease to provide a response. By this time, the patient’s natural immune response may have been completely destroyed. Additionally, late-stage patients generally have very high tumor loads, making cancer eradication that much more difficult. Thus, stimulating a patient’s innate anti-tumor defenses should have a much better chance of working before conventional therapies are employed.

Anti-tumor immunotherapies are often relegated to last-ditch rescue therapy after surgery, radiation and chemotherapy cease to provide a response. By this time, the patient’s natural immune response may have been completely destroyed. Stimulating a patient’s innate anti-tumor defenses should have a much better chance of working before conventional therapies are employed.

How to Generate a Practical Anti-tumor Response

Recently PV-10 (Provecta™), a small-molecule agent, was shown by Provectus Pharmaceuticals to have an almost absolute specificity for tumor cells. PV-10 partitions into the hydrophobic membranes of cancer cells but does not penetrate the cell membranes of normal cells. Figure 1a illustrates the penetrating ability of PV-10 in tumors, while figure Fig. 1b shows a more typical agent with comparable affinity for normal and diseased cells. PV-10 was diluted for this demonstration because at therapeutic concentrations all tumors in the mice would be completely destroyed within 24 hours post injection (Table 1 -- No Table Available).

Subsequent light activation of the control agent, a green photodynamic dye, failed to cure any mice, only partially damaging the tumors while inflicting significant damage on normal tissue. In contrast, mice treated with PV-10 (with or without light) were all cured of their tumors and sustained no damage to healthy tissue or other side effects.

PV-10 has a high affinity for the highly fluid lysosomal membranes of cancer cells and the very low pH (pH-4.0) of the intra-lysosomal environment. Once trapped in this membrane, PV-10 causes the lysosomes to leak or rupture. The cancer cell is quickly destroyed from within by autophagy as the lysosomal hydrolases are released into the cytosol of the cell.  Hersey and coworkers described this process, in a landmark paper in (Not Available) as possibly a new pathway of chemo-induced apoptosis, through which cancer cells destroy themselves.  PV-10 therefore fulfills the criteria for an anti-cancer agent in having almost absolute specificity for tumor tissue, with very rapid clearance from normal tissue. PV-10 shows a half-life after iv injection of 7 hours, but has been detected in significant quantities intratumorally days after intralesional delivery (unpublished data).

Generation of Anti-tumoral Response by PV-10

Table 2 (No Table Available) shows data for immunocompetent mice cured of melanoma tumors by intralesional delivery of PV-10. When challenged 6 months later with transplanted cancer cells, these animals fail to develop tumors. Immunodeficient mice, by contrast, are cured of their initial tumor but fail to develop this protective anti-tumor response. Similarly, mice treated for melanoma by PV-10 treatment, when challenged with an MHC-matched renal adenocarcinoma, develop intradermal tumors produced by these unrelated cancers. Therefore, intralesional treatment with PV-10 produces a highly effective and specific response remarkably similar to that of a vaccine.  Furthermore, in immunocompetent mice, tumor removal by intralesional PV-10 can result in remission of distant untreated tumors (called the “bystander effect”) whereas no similar effect occurs in immunodeficient mice.

Recently completed Phase 1 clinical trials have highlighted the safety and efficacy of PV-10 in patients with Stage III-IV metastatic melanoma. Besides being highly effective against the injected tumors (successful treatment being defined as stable disease, partial regresssion, or complete disappearance of treated lesions), many study participants also exhibited the bystander effect in untreated tumors (Data to be published).  PV-10’s high level of effectiveness against melanoma is in stark contrast to that of approved agents and other new experimental treatments (such as anti-melanoma monoclonal antibodies).

*****

The effectiveness of PV-10 in early human trials is likely a product of its fulfilling the criteria postulated here for effectively engaging the host’s highly evolved immune defenses. PV-10 targets only tumor cells and can generate a long-lasting protective response in immunocompetent animals while failing to do so when the host’s anti-tumor immunity is compromised. PV-10 stimulates anti-tumor defenses in vivo and allows the natural systems to choose the best antigens that generate the most effective response.

With more than one hundred million years of practice, Nature knows best how to fight cancer. PV-10 appears to activate natural immunologic defenses, which in most cases represent the only real chance to beat cancer.